Stock Nucleus - New articles and investments

[STOCKNUCLEUS]

Neoprobe - up 40% in January - doubled each of the past few years. Applied to be listed just waiting for a response any day. Has well over the minimum requirements. Lymphoseek will save lives by detecting any cancer that may have spread to the lymph nodes, 20-30x's more effective, Blue-dye was never tested by the FDA and has many safety concerns attached.

Read more on Neoprobe and other market news @
Stock Nucleus



http://stocknucleus.blogspot.com